Inspire IVF Adjusts IPO Fund Allocation, Strategizes for Risk Diversification Venturing into High-Potential Non-Healthcare Businesses Through Subsidiary "M22"

Inspire IVF Public Company Limited (IVF) announced key decisions from its Annual General Meeting of Shareholders, held on April 17, 2025. These include approval for an adjusted use of IPO proceeds, strategically aimed at fueling future business growth, and the approval of an annual dividend payment for 2024 of THB 0.024 per share, totaling THB 10.56 million. Building on this foundation, the company is actively pursuing a diversification strategy to bolster long-term revenue streams through income and profits from new ventures, while maintaining its core IVF business and planning for market expansion and partnerships in the Middle East.

Ms. Kasinee Kuldiloke, Chief Executive Officer of Inspire IVF Public Company Limited, stated "To support future business growth through adjusted and expanded investment objectives, the shareholders approved a revised IPO fund utilization objective totaling 388 million baht. This objective modifies the original plan, which consisted of three items: 1. Utilizing 84 million baht for working capital, 2. Investing 190 million baht in branch expansion, and 3. Investing 114 million baht in related businesses. The revised objective now comprises four items: 1. Utilizing 158 million baht for working capital, 2. Investing 50 million baht in branch expansion, 3. Investing 30 million baht in related businesses, and 4. Investing 150 million baht in other potential, non-healthcare businesses."

"This new investment objective, focused on high-potential, non-healthcare businesses, will establish a foundation for long-term growth. It will enhance our competitiveness in today's rapidly evolving economic environment and maximize benefits for both the company and our shareholders. Through our subsidiary, 'M22,' we are expanding our investment scope into new business sectors. We are currently studying and developing investments in globally trending sectors, including biomedical chemicals, ICT software, and medical device distribution."

Furthermore, the shareholder meeting approved a dividend payment for the 2024 operating results at a rate of THB 0.024 per share, totaling THB 10.56 million for all 440,000,000 shares. The dividends will be issued to shareholders listed on the record date of March 14, 2025, with the payment date set for April 23, 2025.

"Looking ahead to 2025, the company is prioritizing the creation of synergy with its existing businesses to drive long-term value and growth. We are actively exploring new opportunities, including the non-healthcare market and strategic joint ventures with international partners in the Middle East. Above all, we remain steadfastly committed to our core business: providing comprehensive infertility treatment services, with the unwavering goal of becoming 'a leading international standard fertility center in Thailand and Asia'" Kasinee concluded.

Stay updated on Inspire IVF Public Company Limited, also known as "Inspire IVF," through our Facebook page: https://www.facebook.com/inspireivfthailand and website: https://www.inspireivf.com. For further information, please contact 063-531-8666 or 02-251-8666.

Inspire IVF Adjusts IPO Fund Allocation, Strategizes for Risk Diversification Venturing into High-Potential Non-Healthcare Businesses Through Subsidiary "M22"

ข่าวthe company+o:memberวันนี้

Central Chidlom, under Central Retail, Makes History by Winning 'The Most Innovative Department Store in the World' Award at the Prestigious IGDS World Department Store Summit 2025